Nipocalimab Pivotal Phase 3 Trial Demonstrates Longest Sustained Disease Control in Fcrn Class for Broadest Population of Myasthenia Gravis Patients
Nipocalimab關鍵第3期試驗展示了對肌無力廣泛患者中Fcrn類最長的持續性疾病控制
Nipocalimab Pivotal Phase 3 Trial Demonstrates Longest Sustained Disease Control in Fcrn Class for Broadest Population of Myasthenia Gravis Patients
Nipocalimab關鍵第3期試驗展示了對肌無力廣泛患者中Fcrn類最長的持續性疾病控制
譯文內容由第三人軟體翻譯。